-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectar says iopofosine I 131 posts 61.8% major response rate in Phase 2b WM trial

PUBT·05/05/2026 11:16:56
Listen to the news
Cellectar says iopofosine I 131 posts 61.8% major response rate in Phase 2b WM trial
  • Cellectar BioSciences reported updated 12-month follow-up results from Phase 2b CLOVER WaM study of iopofosine I 131 in relapsed or refractory Waldenström macroglobulinemia, with responses remaining durable and consistent in heavily pretreated patients.
  • Dataset was compiled to meet an FDA request for at least 12 months of follow-up on all patients, strengthening positioning for an accelerated approval filing.
  • Post-BTK inhibitor subgroups showed sustained benefit, supporting a potential role in later-line treatment where options are limited.
  • Efficacy and safety results in patients treated immediately following BTK inhibitor therapy will be presented at ASCO meeting running May 29-June 2, 2026.
  • Recently announced oversubscribed financing of up to USD 140 million is expected to fund confirmatory trial start in 4Q26, supporting an NDA submission strategy tied to accelerated approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050710PRIMZONEFULLFEED9713096) on May 05, 2026, and is solely responsible for the information contained therein.